Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study
Authors:
- Cristina LegnaniCLCristina Legnani
- Alberto TosettoATAlberto Tosetto
- Vittorio PengoVPVittorio Pengo
- Sophie TestaSTSophie Testa
- Domenico PriscoDPDomenico Prisco
- Armando TripodiATArmando Tripodi
- Gualtiero PalaretiGPGualtiero Palareti
- Benilde CosmiBCBenilde Cosmi
- for the PROLONG InvestigatorsFIfor the PROLONG Investigators
- 1 January 2010
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 103 (06) , 1152-1160
Abstract
The PROLONG randomised clinical trial showed that an abnormal D-dimer at one month after vitamin K antagonist (VKA) suspension for a first episode of unprovoked venous thromboembolism (VTE) is associated with a higher risk of recurrence. However, other patient characteristics, such as comorbidities, in combination with D-dimer could also influence the recurrence risk. It was the objective of this study to assess the predictive value of comorbidities and D-dimer in combination for recurrence after withdrawal of VKA in patients enrolled in the PROLONG study. On the day of VKA suspension, the presence of known (coronary, peripheral,cerebral) vascular disease, chronic inflammatory bowel disease, chronic obstructive pulmonary disease, autoimmune disease, diabetes, arterial hypertension, obesity and dyslipidaemias was registered. D-dimer was measured at 30 ± 10 days afterwards. The primary outcome was recurrent objectively documented VTE. Mean follow-up was 2.55 years. An abnormal D-dimer was observed in 44% (135/309) of patients with comorbidities and in 29% (87/299) of patients without (p=0.0003). An on-treatment analysis was conducted in 483 patients in whom VKAs were not resumed. In patients with a normal D-dimer, recurrences were observed in 14.3% (24/168) of patients with comorbidities and 10.8% (22/203) of subjects without (p=ns). In patients with an abnormal D-dimer, recurrences were observed in 24.6% (16/65) patients with comorbidities and 21.3% (10/47) of patients without (p=ns). Although abnormal D-dimer levels were significantly more frequent in patients with comorbidities, D-dimer was an independent risk factor for recurrence and the presence of comorbidities did not increase the risk of recurrence associated with an abnormal post-anticoagulation D-dimer. ClinicalTrials.gov number: NCT00264277 * The PROLONG investigators are listed in the Acknowledgements.Keywords
Funding Information
- Italian Federation of Anticoagulation Clinics
This publication has 26 references indexed in Scilit:
- Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG studyJournal of Thrombosis and Thrombolysis, 2009
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 2008
- A prospective study on cardiovascular events after acute pulmonary embolismEuropean Heart Journal, 2004
- D-Dimer Levels and Risk of Recurrent Venous ThromboembolismJAMA, 2003
- Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2003
- Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital ThrombophiliaCirculation, 2003
- Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is StoppedThrombosis and Haemostasis, 2002
- Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous ThrombosisNew England Journal of Medicine, 2001
- A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous ThromboembolismNew England Journal of Medicine, 1999
- A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous ThromboembolismNew England Journal of Medicine, 1995